Categories
Biotechnology Stock
ACADIA Pharmaceuticals Inc.
We are a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. We currently have five programs in clinical development and several additional programs in preclinical development and discovery stages. In our most advanced proprietary program, we are entering Phase III development ...
more
Accelrys, Inc.
We develop and
commercialize software for computation, simulation, management and mining of
scientific data used by biologists, chemists and materials scientists,
including nanotechnology researchers for product design as well as drug discovery
and development. Our technology and services are designed to meet the needs of
today’s leading research organizations. We are headquartered in ...
more
Acorda Therapeutics, Inc.
We have a history of operating losses and we expect to
continue to incur losses and may never be profitable. As of December 31, 2005, we had an accumulated
deficit of approximately $208.0 million. We had net losses of $35.5 million
and $44.7 million for the years ended December 31, 2005 and December 31,
2004, respectively. We have had operating losses since ...
more
Affymetrix, Inc.
Overview We are engaged in the development, manufacture, sale
and service of consumables and systems for genetic analysis in the life
sciences and clinical healthcare markets and are recognized as a market leader
in creating breakthrough tools that are advancing our understanding of the molecular
basis of life. The markets for our products currently include all aspects of
molecular biology ...
more
Agenus Inc.
Antigenics Inc. (including its subsidiaries, also referred to in this Annual Report on Form 10-K as “Antigenics”, the “Company”, “we”, “us”, and “our”) is a biotechnology company developing technologies and products to treat cancers and infectious diseases, primarily based on immunological approaches. Our most advanced product ...
more
Albany Molecular Research, Inc.
Overview Albany Molecular Research, Inc. (“the Company”), a Delaware corporation incorporated on June 20, 1991, is a global chemistry-based drug discovery and development company focused on identifying and developing novel biologically active small molecules with applications in the drug market. Our core business consists of a fee-for service contract services platform ...
more
Alexion Pharmaceuticals, Inc.
We are a biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical
conditions. We are engaged in the discovery and development of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. Since our incorporation in ...
more
Allos Therapeutics, Inc.
Strategy Our goal is to
build a profitable company by generating income from products we develop and
commercialize, either alone or with one or more potential strategic partners.
The key elements of our business strategy are to: · Focus on the oncology market. We intend to continue to focus
our drug development efforts on the oncology market. We ...
more
Amylin Pharmaceuticals, Inc.
School
Health Industry Advisory Board, the Harvard Business School Dean’s Advisory
Board, the Advisory Board for the Kellogg Center for Executive Women, and the
University of California, San Diego Health Sciences Advisory Board. Ms. Graham
received an M.B.A. from Harvard University. Mr. Bradbury
has served as our
President and Chief Operating Officer since June 2006, serving as our ...
more
Arena Pharmaceuticals, Inc.
We are a clinical-stage biopharmaceutical company focused on
discovering, developing and commercializing oral drugs in four major
therapeutic areas: cardiovascular, central nervous system, inflammatory and
metabolic diseases. Our most advanced drug candidate, lorcaserin hydrochloride,
or lorcaserin, is being investigated in a Phase 3 clinical trial program
for the treatment of obesity. ...
more
ARIAD Pharmaceuticals, Inc.
, OUR FINANCIAL CONDITION AND OUR RESULTS OF OPERATIONS. Risks Relating to Our Business We have only one product candidate in clinical trials, AP23573, and we and our partners may never succeed in developing marketable products or generating product revenues. We are a biopharmaceutical company focused on the discovery and development of drugs ...
more
ArQule, Inc.
STRATEGY Development of our products is at an early stage and
is based on scientific platforms that are unproven. We may not successfully
develop a drug candidate that becomes a commercially viable drug. The discovery and development of drugs is inherently
risky and involves a high rate of failure. Discovering and developing
commercial drugs are relatively new to us. Our drug candidates ...
more
Array BioPharma Inc.
We have
a history of losses and may not achieve or sustain profitability. We are at an early stage
of executing our business plan, and we have a limited history of developing and
out-licensing our proprietary drug candidates and offering our drug discovery
capabilities. We have incurred significant operating and net losses and
negative cash flows from operations since our inception. As of ...
more
Bioanalytical Systems, Inc.
The Company operates in
two business segments – contract research services and research products, both of
which address the bioanalytical, preclinical, and clinical research needs of drug
developers. Both segments arose out of the Company’s expertise in a number of core
technologies designed to quantify trace chemicals in complex matrices. The Company
evaluates performance and ...
more
BioCryst Pharmaceuticals, Inc.
" -->ITEM 1. BUSINESSForward-Looking Statements and Risk Factors This report includes forward-looking statements. In particular, statements about our
expectations, beliefs, plans, objectives or assumptions of future events or performance are
contained or incorporated by reference in this report. We have based these forward-looking
statements on our current ...
more
